Grant: Master's Award: Canada Graduate Scholarships
University of Guelph
$17,500.00
Analysis of oxidative stress on off-target infection of activated T cells by oncolytic vesicular stomatitis virus
FY 2021-22
Summary
Oncolytic virotherapy is a form of cancer therapy that utilizes oncolytic viruses (OVs) to preferentially infect and kill tumour cells. We have previously demonstrated that some OVs in clinical trials likely lack efficacy due to the off-target infection of activated T cells when used in multi-dosing protocols. An increase in oxidative stress due to the increase in reactive oxygen species (ROS) during viral replication may contribute to multiple aspects of viral pathogenesis. This project looks at the ability of some antioxidants, compounds that inhibit oxidation and protect cells from ROS-mediated damage, to prevent off-target infection of activated CD4+ and CD8+ T cells. If antioxidants can prevent off-target viral infection of T cells, co-administering antioxidants during a rapid multi-dosing protocol with OVs has the potential to increase their efficacy. Thus far, the antioxidants N-acetyl L cysteine and catalase have proven promising candidates for improving cancer immunotherapies by preventing T cell of target infection with vesicular stomatitis virus. This project will be extended to a murine melanoma survival model to better determine which combination therapies extend survival.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
467024
Name
Vanderkamp Sierra
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Analysis of oxidative stress on off-target infection of activated T cells by oncolytic vesicular stomatitis virus
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Immunotherapy; Immunology; Oncolytic Virotherapy; Virology
Abstract
Oncolytic virotherapy is a form of cancer therapy that utilizes oncolytic viruses (OVs) to preferentially infect and kill tumour cells. We have previously demonstrated that some OVs in clinical trials likely lack efficacy due to the off-target infection of activated T cells when used in multi-dosing protocols. An increase in oxidative stress due to the increase in reactive oxygen species (ROS) during viral replication may contribute to multiple aspects of viral pathogenesis. This project looks at the ability of some antioxidants, compounds that inhibit oxidation and protect cells from ROS-mediated damage, to prevent off-target infection of activated CD4+ and CD8+ T cells. If antioxidants can prevent off-target viral infection of T cells, co-administering antioxidants during a rapid multi-dosing protocol with OVs has the potential to increase their efficacy. Thus far, the antioxidants N-acetyl L cysteine and catalase have proven promising candidates for improving cancer immunotherapies by preventing T cell of target infection with vesicular stomatitis virus. This project will be extended to a murine melanoma survival model to better determine which combination therapies extend survival.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vanderkamp, Sierra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~